# US 9,434,777 B2 · Neuregulin peptides and their use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,434,777 B2
- Document ID: US9434777B2
- Status: Granted
- Kind: B2
- Application number: 14/657,899
- Filed: 2015-03-13
- Published: 2016-01-14
- Granted: 2016-09-06
- Earliest claimed: 2008-11-28
- Assignees: Zensun (Shanghai) Science & Technology, Co., Ltd.
- Applicants: Zensun (Shanghai) Science & Technology Limited
- Inventors: Mingdong Zhou
- Web page: https://patentgrep.com/patent/US9434777B2

## CPC

- C07K 14/4756: {Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor}
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 38/1883: {Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor}
- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Neuregulin peptides useful, for example, in methods and compositions comprising preventing, treating or delaying various diseases or disorders are described.

## Claims

### Claim 1

A method for treating heart failure in a subject in need thereof comprising administering intravenously or subcutaneously to the subject and effective amount of neuregulin peptide consisting of the amino acid sequence of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7 or SEQ ID NO:9.

### Claim 2 (depends on 1)

The method of claim 1, wherein the neuregulin peptide consists of the amino acid sequence of SEQ ID NO:3.

### Claim 3 (depends on 2)

The method of claim 2, wherein the neuregulin peptide is administered intravenously.

### Claim 4 (depends on 2)

The method of claim 2, wherein the neuregulin peptide is administered subcutaneously.

### Claim 5 (depends on 1)

The method of claim 1, wherein the neuregulin peptide consists of the amino acid sequence of SEQ ID NO:5 and is administered intravenously.

### Claim 6 (depends on 1)

The method of claim 1, wherein the neuregulin peptide consists of the amino acid sequence of SEQ ID NO:5 and is administered subcutaneously.

### Claim 7 (depends on 1)

The method of claim 1, wherein the neuregulin peptide consists of the amino acid sequence of SEQ ID NO:7.

### Claim 8 (depends on 7)

The method of claim 7, wherein the neuregulin peptide is administered intravenously.

### Claim 9 (depends on 7)

The method of claim 7, wherein the neuregulin peptide is administered subcutaneously.

### Claim 10 (depends on 1)

The method of claim 1, wherein the neuregulin peptide consists of the amino acid sequence of SEQ ID NO:9.

### Claim 11 (depends on 10)

The method of claim 10, wherein the neuregulin peptide is administered intravenously.

### Claim 12 (depends on 10)

The method of claim 10, wherein the neuregulin peptide is administered subcutaneously.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any one of claim 1, 2, 3, 4, 5-7, 8-10, 11 or 12, wherein the subject is human.